In BKC's SA article "Resverlogix: the science is getting BETter" he states something that Don has said he is working on and that is raising funds through a licensing deal. BKC suggests perhaps a deal for Apabetalone rights to Japan or Latin America.  I think additional attractive non-core markets would be the Middle East and Russia/Eastern Europe.  

In any event, I know that others have been suggesting they think that Eastern is perhaps interested in becoming a full on pharma. While I disagree with this because I think that the time and money spent to effect this would be counterproductive, I have been thinking that Eastern might be interested in obtaining the rights to one of these non-core markets. I think if Eastern was to do a deal which saw them increase and extend the LoC guarantee for a combination of more warrants, increased claim on tax pools and the rights to Apabetalone in one or more non-core markets it would be beneficial to them as well as supportive to their investment.  I think down the road the exclusive rights to a market would probably result in a higher ROI for a non pharma than trying to reinvent the pharma wheel.  JMO